The Enterprise Value as of December 2024 (TTM) for Candel Therapeutics, Inc. (CADL) is 392.63M

According to Candel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 392.63M. This represents a change of 225.11% compared to the average of 120.77M of the last 4 quarters.

Candel Therapeutics, Inc. (CADL) Historical Enterprise Value (quarterly & annually)

How has CADL Enterprise Value performed in the past?

The mean historical Enterprise Value of Candel Therapeutics, Inc. over the last ten years is 109.14M. The current 392.63M Enterprise Value has changed 35.87% with respect to the historical average. Over the past ten years (40 quarters), CADL's Enterprise Value was at its highest in in the September 2024 quarter at 221.32M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Candel Therapeutics, Inc. (CADL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Candel Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Candel Therapeutics, Inc. (CADL) Average Enterprise Value

How has CADL Enterprise Value performed in the past?

The current Enterprise Value of Candel Therapeutics, Inc. (CADL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Candel Therapeutics, Inc. (CADL) Enterprise Value vs. Peers

How is CADL’s Enterprise Value compared to its peers?

Candel Therapeutics, Inc.’s Enterprise Value is greater than Aerovate Therapeutics, Inc. (43.78M), greater than Adagene Inc. (9.01M), greater than Acrivon Therapeutics, Inc. Common Stock (152.40M), greater than Rezolute, Inc. (247.72M), greater than AN2 Therapeutics, Inc. (7.29M), greater than Molecular Partners AG (107.67M), less than Mineralys Therapeutics, Inc. (532.80M), less than Pharvaris N.V. (675.36M), greater than PepGen Inc. (104.20M), greater than PMV Pharmaceuticals, Inc. (41.30M), greater than Acurx Pharmaceuticals, Inc. (8.43M), greater than Monopar Therapeutics Inc. (122.23M), greater than Enochian Biosciences, Inc. (123.24M), greater than Indaptus Therapeutics, Inc. (3.94M), greater than Tempest Therapeutics, Inc. (33.90M), greater than Comera Life Sciences Holdings, Inc. (-1590126.00), greater than Forte Biosciences, Inc. (13.24M), less than Bionomics Limited (1.26B), greater than OKYO Pharma Limited (34.76M), greater than Anebulo Pharmaceuticals, Inc. (29.20M), greater than Cingulate Inc. (5.52M),

Build a custom stock screener for Candel Therapeutics, Inc. (CADL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Candel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Candel Therapeutics, Inc. (CADL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Candel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.